ACME RESOURCES CORP.

INTERIM CONDENSED FINANCIAL STATEMENTS
(Expressed in Canadian Dollars, Unaudited)

FOR THE NINE MONTHS ENDED JUNE 30, 2018 AND 2017

NOTICE TO READER: *The accompanying unaudited interim condensed financial statements have been prepared by and are the responsibility of management. The unaudited interim financial statements for the nine-month periods ended June 30, 2018 and June 30, 2017 have not been reviewed by an independent external auditor.*

ACME RESOURCES CORP.

INTERIM CONDENSED FINANCIAL STATEMENTS
(Expressed in Canadian Dollars, Unaudited)

FOR THE NINE MONTHS ENDED JUNE 30, 2018 AND 2017

I N D E X

	PAGE
CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION	1
CONDENSED INTERIM STATEMENTS OF COMPREHENSIVE LOSS	2
CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (DEFICIENCY)	3
CONDENSED INTERIM STATEMENTS OF CASH FLOWS	4
NOTES TO INTERIM FINANCIAL STATEMENTS	5 -17

ACME RESOURCES CORP.

CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION
(Expressed in Canadian Dollars, Unaudited)

	June 30, 2018	September 30, 2017
ASSETS		
CURRENT		
Cash	$ 401,296	$ 17,064
Deferred transaction costs	96,032	-
	$ 497,328	$ 17,064
LIABILITIES		
CURRENT		
Accounts payable and accrued liabilities	$ 111,443	$ 29,839
	111,443	29,839
SHAREHOLDERS' EQUITY (DEFICIENCY)		
SHARE CAPITAL (note 6 (a))	1,030,088	395,456
SHARES TO BE ISSUED	-	50,000
RESERVE FOR SHARE-BASED PAYMENTS (note 6 (b))	-	44,747
CONTRIBUTED SURPLUS	150,000	-
ACCUMULATED DEFICIT	(794,203)	(502,978)
	385,885	(12,775)
	$ 497,328	$ 17,064

INCORPORATION, NATURE OF OPERATIONS AND GOING CONCERN (note 1)
SUBSEQUENT EVENTS (note 13)

Approved by the Board:

(Signed) " *John Siriunas* " , Director

(Signed) " *Brian Howlett* " , Director

See the accompanying notes.

ACME RESOURCES CORP.

CONDENSED INTERIM STATEMENTS OF COMPREHENSIVE LOSS
(Expressed in Canadian Dollars, Unaudited)

FOR THE NINE MONTHS ENDED JUNE 30, 2018 AND 2017

	Three months ended		Nine months ended	
	June 30, 2018	June 30, 2017	June 30, 2018	June 30, 2017
EXPENSES				
Bank charges	$ 94	$ 58	$ 385	$ 230
Corporate development	3,242	2,111	12,991	7,104
Regulatory and filing fees	5,574	2,273	33,388	6,501
Consulting fees	54,601	-	207,149	-
General and administrative	11,836	2,000	51,837	5,500
Professional fees	8,972	-	30,222	4,212
NET LOSS AND COMPREHENSIVE LOSS FOR THE PERIOD	$ 84,319	$ 6,442	$ 335,972	$ 23,547
Loss per share:				
Basic and diluted loss per share	$ 0.016	$ 0.005	$ 0.109	$ 0.022
Weighted average number of common share outstanding	5,272,190	1,200,190	3,087,860	1,073,590

See the accompanying notes.

ACME RESOURCES CORP.

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (DEFICIENCY)
(Expressed in Canadian Dollars, Unaudited)

FOR THE NINE MONTHS ENDED JUNE 30, 2018 AND 2017

	Share Capital Common Shares	Share Capital Amount	Reserve for Shares to be issued	Share-based payments	Contributed Surplus	Accumulated deficit	Total
Balance, September 30, 2016	820,390	$ 351,304	$ 20,000	$ 44,747	$ -	($ 452,899)	($ 36,848)
Shares issued for cash	379,800	44,152	-	-	-	-	44,152
Net loss for the period	-	-	-	-	-	(23,547)	(23,547)
Balance, June 30, 2017	1,200,190	$ 395,456	$ 20,000	$ 44,747	$ -	($ 476,446)	($ 16,243)
Balance, September 30, 2017	1,200,190	$ 395,456	$ 50,000	$ 44,747	$ -	($ 502,978)	($ 12,775)
Shares issued pursuant to prior period private placements	320,000	50,000	(50,000)	-	-	-	-
Shares issued pursuant to current period private placements, net of share issue costs	496,000	62,000	-	-	-	-	62,000
Cancellation of escrowed Founder's shares (note 6(a))	(150,000)	(150,000)	-	-	150,000	-	-
Shares issued pursuant to current period private placements, net of share issue costs	2,006,000	497,632	-	-	-	-	497,632
Shares issued pursuant to debt conversion	1,400,000	175,000	-	-	-	-	175,000
Fair value of cancelled stock options (note 6(b))	-	-	-	(44,747)	-	44,747	-
Net loss for the period	-	-	-	-	-	(335,972)	(335,972)
Balance, June 30, 2018	5,272,190	$ 1,030,088	$ -	$ -	$ 150,000	($ 794,203)	$ 385,885

See the accompanying notes.

ACME RESOURCES CORP.

CONDENSED INTERIM STATEMENTS OF CASH FLOWS
(Expressed in Canadian Dollars, Unaudited)

FOR THE NINE MONTHS ENDED JUNE 30, 2018 AND 2017

	2018	2017
CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES:		
Net loss for the period	($ 335,972)	($ 23,547)
Adjust for changes in working capital balance:		
Increase (decrease) in accounts payable and accrued liabilities	256,604	(20,079)
Cash used in operations	(79,368)	(43,626)
CASH USED IN INVESTING ACTIVITIES:		
Increase in deferred transaction costs	(96,032)	-
Cash used in investing	(96,032)	-
CASH PROVIDED BY FINANCING ACTIVITIES:		
Issuance of common shares, net of share issue costs	559,632	44,152
Cash provided by financing	559,632	44,152
INCREASE IN CASH POSITION	384,232	526
CASH POSITION AT BEGINNING OF THE PERIOD	17,064	903
CASH POSITION AT END OF THE PERIOD	$ 401,296	$ 1,429
SUPPLEMENTARY CASH FLOW INFORMATION:		
Issuance of common shares for debt conversion	$ 175,000	$ -

See the accompanying notes.

ACME RESOURCES CORP.

NOTES TO INTERIM CONDENSED FINANCIAL STATEMENTS
(Expressed in Canadian Dollars, Unaudited)

FOR THE NINE MONTH PERIODS ENDED JUNE 30, 2018 AND 2017

1. INCORPORATION, NATURE OF OPERATIONS AND GOING CONCERN:

ACME Resources Corp. (the “Company”) was incorporated by articles of incorporation under *the Business Corporations Act* of Ontario on February 27, 2008. The Company is classified as a Capital Pool Company (“CPC”) for regulatory purposes as defined in Policy 2.4 of the TSX Venture Exchange (the “TSXV”, or the “Exchange”). As a CPC, the Company’s principal business was to identify, evaluate and acquire assets, properties or businesses which would constitute a qualifying transaction in accordance with Policy 2.4 of the Exchange (“Qualifying Transaction”). Such a transaction will be subject to shareholder and regulatory approval. The Company’s principal office is suite 200 – 20 Adelaide Street East, Toronto, Ontario, M5C 2T6.

On January 28, 2010, the Company received final receipts for a prospectus and thereafter began trading on the TSXV (Tier 2) as a CPC under the symbol ACY.P. However, as the Company did not complete a Qualifying Transaction within the necessary timeframe, the Company’s listing has been transferred to the NEX board of the Exchange (“NEX”). The NEX trading symbol is ACY.H. Trading on the TSXV was suspended by the TSXV on February 22, 2018 and the Company’s common shares were subsequently delisted from the NEX by the TSXV. The Company has abandoned pursuing a qualifying transaction, as defined in Policy 2.4 of the Exchange.

The financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred significant net losses and negative cash flows from operations in prior years. The Company incurred a net loss of $335,972 (period ended June 30, 2017 - $23,547) during the period ended June 30, 2018 and, as of that date the Company’s deficit was $794,203 (June 30, 2017 - $476,446). Should the Company be unable to continue as a going concern, the realization of assets may be at amounts significantly less than carrying values.

The continuation of the Company as a going concern is dependent on its ability to obtain additional equity capital to finance existing operations. These financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statement of financial position classifications that would be necessary were the going concern assumption inappropriate.

2. BASIS OF PRESENTATION:

Statement of Compliance-

These condensed interim financial statements have been prepared in accordance with International Accounting Standard (“IAS”) 34, “Interim Financial Reporting” using accounting policies consistent with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and Interpretations issued by the International Financial Reporting Interpretations Committee (“IFRIC”). The accounting policies followed in these condensed interim financial statements are the same as those applied in the Company’s most recent annual financial statements for the year ended September 30, 2017. The condensed interim financial statements should be read in conjunction with the Company’s annual financial statements for the year ended September 30, 2017.

The financial statements were authorized for issue by the Board of Directors on August 28, 2018.

2. BASIS OF PRESENTATION (continued):

Basis of Measurement-

The financial statements have been prepared on a historical cost basis and are presented in Canadian dollars, which is also the Company's functional currency.

Critical judgments in applying accounting policies-

The preparation of financial statements in conformity with IFRS requires that management make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes to the financial statements. Actual results may differ from those estimates.

These financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant estimates and judgments used in the preparation of these financial statements include, but are not limited to, stock option valuations, going concern assumption, deferred income tax recognition and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expenditures during the reporting period. Actual results could differ from management's best estimates.

3. SIGNIFICANT ACCOUNTING POLICIES:

INCOME TAXES:

Income tax on the profit or loss for the periods presented comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity.

Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at period end, adjusted for amendments to tax payable with regards to previous years.

Deferred tax is recorded using the statement of financial position liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes; the initial recognition of assets or liabilities that affect neither accounting nor taxable loss; and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future.

3. SIGNIFICANT ACCOUNTING POLICIES (continued):

INCOME TAXES (continued):

The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the statement of financial position date.

SHARE-BASED PAYMENTS:

Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of the equity instruments at the grant date. Details regarding the determination of the fair value of equity-settled share-based transactions are set out in the share-based payment note. The fair value is measured at grant date and each tranche is recognized on a graded-vesting basis over the period in which options vest. At the end of each reporting period, the Company revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognized in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to share-based payment reserve. Equity-settled share-based payment transactions with parties other than employees are measured at the fair value of the goods or services received, except where that fair value cannot be estimated reliably, in which case they are measured at the fair value of the equity instruments granted, measured at the date the entity obtains the goods or the counterparty renders the service. For those options that expire or are forfeited after vesting, the recorded value is transferred to accumulated deficit.

SHARE ISSUE COSTS:

Transaction costs directly attributable to financing transactions are reported as deferred financing costs until the transactions are completed, if the completion of the transaction is considered to be probable. Share issue costs are charged to share capital when the related shares are issued. Costs relating to financing transactions that are not completed, or for which successful completion is considered unlikely, are charged to operations. Agent's options are valued using the Black-Scholes Option Pricing Model.

DEFERRED TRANSACTION COSTS:

The Company defers costs relating to the evaluation of potential qualifying transactions. However, if the Company determines that a specific qualifying transaction should not be concluded, the costs associated with the specific qualifying transaction are charged to operations in the current period.

LOSS PER SHARE:

Loss per share is based on the weighted average number of common shares of the Company outstanding during the period. The diluted loss per share reflects the potential dilution of common share equivalents, such as outstanding share options and warrants, in the weighted average number of common shares outstanding during the period, if dilutive. There is no dilution effect for the year as the Company is in a loss position.

3. SIGNIFICANT ACCOUNTING POLICIES (continued):

FINANCIAL INSTRUMENTS:

Financial assets –

All financial assets are initially recorded at fair value and designated upon inception into one of the following four categories: held-to-maturity, available-for-sale, loans and receivables or at fair value through profit or loss (“FVTPL”).

Financial assets classified as FVTPL are measured at fair value with unrealized gains and losses recognized through earnings. The Company’s cash is classified as FVTPL.

Financial assets classified as loans and receivables and held-to-maturity are measured at amortized cost. Financial assets classified as available-for-sale are measured at fair value with unrealized gains and losses recognized in other comprehensive income (loss) except when there is objective evidence that the asset is impaired. The Company’s share subscriptions receivable are classified as loans and receivables.

Transactions costs associated with FVTPL financial assets are expensed as incurred, while transaction costs associated with all other financial assets are included in the initial carrying amount of the asset.

Financial liabilities –

All financial liabilities are initially recorded at fair value and designated upon inception as FVTPL or other financial liabilities.

Financial liabilities classified as other financial liabilities are initially recognized at fair value less directly attributable transaction costs. After initial recognition, other financial liabilities are subsequently measured at amortized cost using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or, where appropriate, a shorter period. The Company’s accounts payable and accrued liabilities are classified as other financial liabilities.

Financial liabilities classified as FVTPL include financial liabilities held-for-trading and financial liabilities designated upon initial recognition as FVTPL. Derivatives, including separated embedded derivatives are also classified as held-for-trading unless they are designated as effective hedging instruments. Fair value changes on financial liabilities classified as FVTPL are recognized through the statement of comprehensive income (loss). At June 30, 2018, the Company has not classified any financial liabilities as FVTPL.

3. SIGNIFICANT ACCOUNTING POLICIES (continued):

FINANCIAL INSTRUMENTS (continued):

Impairment of financial assets –

The Company assesses at each date of the statement of financial position whether a financial asset is impaired.

a) Assets carried at amortized cost

If there is objective evidence that an impairment loss on assets carried at amortized cost has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows discounted at the financial asset's original effective interest rate. The carrying amount of the asset is then reduced by the amount of the impairment. The amount of the loss is recognized in profit or loss.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, the previously recognized impairment loss is reversed to the extent that the carrying value of the asset does not exceed what the amortized cost would have been had the impairment not been recognized. Any subsequent reversal of an impairment loss is recognized in profit or loss.

In relation to accounts receivable, a provision for impairment is made and an impairment loss is recognized in profit and loss when there is objective evidence (such as the probability of insolvency or significant financial difficulties of the debtor) that the Company will not be able to collect all of the amounts due under the original terms of the invoice. The carrying amount of the receivable is reduced through use of an allowance account. Impaired debts are written off against the allowance account when they are assessed as uncollectible.

b) Available-for-sale

If an available-for-sale asset is impaired, an amount comprising the difference between its cost and its current fair value, less any impairment loss previously recognized in profit or loss, is transferred from equity to profit or loss.

3. SIGNIFICANT ACCOUNTING POLICIES (continued):

FINANCIAL INSTRUMENTS (continued):

Financial instruments recorded at fair value-

Financial instruments recorded at fair value on the statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels: Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and Level 3 - valuation techniques using inputs for the asset or liability that are not based on observable market data (unobservable inputs). As of June 30, 2018 and September 30, 2017, cash was the Company's only financial instrument that is recorded at fair value on the statements of financial position, which is classified as level 1.

PROVISIONS

General

Provisions are recognized when (a), the Company has a present obligation (legal or constructive) as a result of a past event, and (b), it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. The expense relating to any provision is presented in the statement of comprehensive loss, net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre tax rate that reflects, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

4. CURRENT AND FUTURE ACCOUNTING AND REPORTING CHANGES:

<u>Effective for annual periods beginning on or after January 1, 2018</u>

IFRS 9, Financial Instruments – Classification and Measurement, is a new standard on financial instruments that will replace IAS 39, Financial Instruments: Recognition and Measurement. IFRS 9 addresses classification and measurement of financial assets and financial liabilities as well as derecognition of financial instruments. IFRS 9 has two measurement categories for financial assets: amortized cost and fair value. All equity instruments are measured at fair value. A debt instrument is at amortized cost only if the entity is holding it to collect contractual cash flows and the cash flows represent principal and interest.

Otherwise it is at fair value through profit or loss.

The Company has not early adopted these revised standards and none of these standards are expected to have a material effect on the financial statements.

5. BANK OVERDRAFT:

The Company has overdraft protection of up to $3,500 (2017 - $3,000). The overdraft balance is subject to an annual interest rate of 21%.

6. SHARE CAPITAL:

a) Common shares:

Authorized: Unlimited number of common shares

Escrowed Shares

As of June 30, 2018, no (June 30, 2017 - 750,000 pre-consolidation) common shares are held in escrow. Under the escrow agreement, 10% of the escrowed common shares will be released from escrow following issuance of the Final Exchange Bulletin by the Exchange as to completion of the Qualifying Transaction as defined by Exchange policies, and 15% will be released every six months following the initial release over a period of thirty-six months, unless otherwise permitted by the Exchange. Since the Company abandoned the pursuit of a Qualifying transaction, the 750,000 (150,000 post consolidation) previously escrowed shares were cancelled in accordance with TSXV policy. The paid-up capital amount of the forfeited shares was transferred to contributed surplus from common share capital.

Share consolidation

The Company completed a 5 for 1 share consolidation during the six-month period ended March 31, 2018. The share consolidation was effective February 16, 2018. All share, option and per share amounts in these financial statements have been retroactively restated to reflect this share consolidation.

Shares Issued for cash

By way of private placements, the Company issued the following common shares for cash consideration in the current period:

I) 1,600,000 (320,000 post consolidation) common shares for gross proceeds of $50,000; and
II) 2,480,000 (496,000 post consolidation) common shares for gross proceeds of $62,000.

By way of private placements and during the current period, the Company issued 2,006,000 common shares for gross cash proceeds of $501,500. Share issue costs of $3,867 were incurred on these private placements.

6. SHARE CAPITAL (continued):

a) Common shares (continued):

Shares Issued for cash (continued)

On December 28, 2016, the Company issued 1,899,000 (379,800 post consolidation) common shares for gross cash proceeds of $47,475. Finders fees of $3,323 were paid to an eligible finder in connection with these private placements.

Shares for debt

In the current period and subsequent to the share consolidation, the Company issued 1,400,000 common shares in repayment of $175,000 of debt.

b) Stock options and share-based compensation:

The Company adopted a stock option plan (the "Stock Option Plan") under which it can grant options to directors, officers, employees, and consultants for up to 10% of the issued and outstanding common shares. Under the plan, the exercise price of an option may not be less than the closing market price during the trading day immediately preceding the date of the grant of the option, less any applicable discount allowed by the TSXV.

Any common shares acquired pursuant to the exercise of options prior to the completion of the qualifying transaction must be deposited in escrow and will be subject to escrow until the Final Exchange Bulletin is issued.

The Company cancelled 41,828 (209,142 pre-consolidation) stock options during the period. Accordingly, the fair value of the cancelled stock options of $44,747 was reclassified from reserve for share-based payments to accumulated deficit during the current period.

As of June 30, 2018, the Company had no (June 30, 2017 – 49,434; 247,168 pre-consolidation) stock options outstanding. The options outstanding at June 30, 2017 had an exercise price of $1 (2016 - $0.20 pre-consolidation) and an expiry date of January 28, 2020.

c) Warrants:

As of June 30, 2018 and 2017, there were no warrants outstanding.

7. CAPITAL MANAGEMENT:

Capital is comprised of the Company's shareholders' equity(deficiency), which includes share capital, shares to be issued, reserve for share-based payments, contributed surplus and accumulated deficit. As at June 30, 2018, the Company's shareholders' equity was $385,885 (June 30, 2017 – shareholders' deficiency of $16,243) and it had no outstanding long-term debt. The Company's objectives when managing capital are to maintain financial strength and to protect its ability to meet its on-going liabilities, to continue as a going concern, to maintain creditworthiness and to maximize returns for shareholders over the long-term.

In order for the Company to pay for administrative costs, the Company expects to raise additional amounts externally as needed.

The Company is not exposed to any external capital requirements, other than any minimum listing requirements that may apply. There were no changes in the Company's management of capital during the period ended June 30, 2018.

8. FINANCIAL RISK FACTORS:

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Credit risk -

The Company's credit risk is primarily attributable to cash included in current assets. The Company has no material concentration of credit risk arising from operations. Cash consist of deposits held with a Chartered Canadian bank, from which management believes the risk of loss is remote. Management believes that credit risk with respect to receivables is minimal.

Liquidity risk -

The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. The Company currently has current liabilities of $111,443 (September 30, 2017 - $29,839) and current assets of $497,328 (September 30, 2017 - $17,064). The Company's accounts payable and accrued liabilities have contractual maturities of less than 60 days and are subject to normal trade terms. The ability of the Company to maintain its working capital surplus is dependent on its ability to secure additional equity or debt financing.

Market risk -

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, foreign exchange rates and equity prices.

ACME RESOURCES CORP.

NOTES TO INTERIM CONDENSED FINANCIAL STATEMENTS
(Expressed in Canadian Dollars, Unaudited)

FOR THE NINE MONTH PERIODS ENDED JUNE 30, 2018 AND 2017

8. FINANCIAL RISK FACTORS (continued):

Market risk (continued)-

i) Interest rate risk

The Company has cash balances and no interest-bearing debt. The Company is not exposed to any significant interest rate risk.

ii) Foreign currency risk

The Company does not have assets or liabilities denominated in foreign currencies and is therefore not exposed to foreign exchange risk arising from transactions denominated in a foreign currency.

9. RELATED PARTY TRANSACTIONS:

Transactions with related parties are incurred in the normal course of business.

Related party transactions are disclosed below, unless they have been disclosed elsewhere in the financial statements.

During the nine months ended June 30, 2018, consulting fees for corporate management and administrative services in the amount of $ 60,350 (2017 - $nil) were charged by the Chief Executive Officer of the Company.

During the nine month period ended June 30, 2018, directors fees amounting to $ 84,375 (2017 - $nil) were paid to four directors, in aggregate.

The Company's key management personnel has the authority and responsibility for planning, directing and controlling the activities of the Company and consists of its Directors, Chief Executive Officer and Chief Financial Officer. Total compensation paid to the Company's key management personnel during the nine months ended June 30, 2018 was $ 144,725 (2017 - $nil). No share based-payments, post-employment or other long-term benefits were incurred with respect to key management personnel in respect of the forgoing periods.

10. SEGMENTED INFORMATION:

The Company's principal business has historically been the identification and evaluation of companies, assets or businesses with a view to completing a Qualifying Transaction in accordance with Policy 2.4 of the Exchange. All of the Company's assets and expenses are in Canada (see note 1).

ACME RESOURCES CORP.

NOTES TO INTERIM CONDENSED FINANCIAL STATEMENTS
(Expressed in Canadian Dollars, Unaudited)

FOR THE NINE MONTH PERIODS ENDED JUNE 30, 2018 AND 2017

11. CASH:

The proceeds raised from the issuance of share capital may only be used to identify and evaluate assets of businesses for future investment, with the exception that the lesser of 30% of the gross proceeds and $210,000 may be used to cover prescribed costs of issuing the common shares, other than Agent Commissions and fees, and general and administrative expense of the Company. These restrictions apply until completion of a Qualifying Transaction by the Company as defined under the policies of the Exchange. The Company had exceeded these limits as at March 28, 2018, the date of delisting from the NEX by the TSXV. The Company has abandoned pursuing a Qualifying Transaction.

12. INCOME TAXES:

(a) The Company's provision for income taxes differ from the amounts computed by applying the basic current tax rates to loss for the period before taxes, as shown in the following table:

	2018	2017
Loss before income taxes	($ 335,972)	($ 23,547)
Expected combined statutory income tax rate	26.5%	26.5%
Income tax benefit at the combined Canadian statutory rate	(89,033)	(6,240)
Tax benefits not recognized	89,033	6,240
	$ -	$ -

(b) The tax effects of temporary differences that give rise to deferred income tax assets at June 30, 2018 and June 30, 2017 are as follows:

	2018	2017
Deferred income tax assets:		
Non-capital loss carry forward	$ 237,343	$ 513,070
Share issue costs	6,698	7,840
Cumulative eligible capital	2,228	2,395
Less: assets not recognized	(246,269)	(523,305)
Deferred income tax assets recognized	$ -	$ -

ACME RESOURCES CORP.

NOTES TO INTERIM CONDENSED FINANCIAL STATEMENTS
(Expressed in Canadian Dollars, Unaudited)

FOR THE NINE MONTH PERIODS ENDED JUNE 30, 2018 AND 2017

12. INCOME TAXES (continued):

(c) The Company has Canadian non-capital losses of approximately $895,635 that are available to reduce income otherwise taxable in future years. These losses if not used will expire as follows:

2028	$ 1,689
2029	3,669
2030	52,018
2031	88,379
2032	199,714
2033	38,740
2034	32,468
2035	50,835
2036	45,558
2037	46,593
2038	335,972
	$ 895,635

(d) During 2018, the Company paid $nil (2017 - $nil) in respect of income taxes.

13. SUBSEQUENT EVENTS:

Amended and Restated Amalgamation Agreement

On July 12, 2018, the Company entered into an Amended and Restated Amalgamation Agreement (the "Amalgamation Agreement") to acquire 100% of the issued share capital of Rapid Dose Therapeutics Inc. ("RDT") in a Reverse Take-Over transaction (the "Transaction") payable by the issuance of approximately 57,641,200 common shares of the Company.

About RDT

RDT is a private Canadian bio-technology company which provides proprietary enhanced drug delivery technologies designed to improve patient outcomes. RDT owns a proprietary oral fast-dissolving drug delivery system, QuickStrip™, which is capable of rapidly releasing into the blood stream a list of pharmaceuticals, emulsified oils and over-the-counter medicines without beingdegraded or modified by first pass metabolism in the liver. RDT also provides product innovation, production and consultation to the pharmaceutical and healthcare manufacturing industry.

RDT currently has 57,641,200 common shares (each a "RDT Share") and 840,000 warrants (each a "RDT Warrant") outstanding. Each RDT Warrant entitles the holder to acquire one RDT Share at an exercise price of $0.75 at any time within 5 months after the RDT Shares are listed for trading on the Canadian Securities Exchange ("CSE") or other Canadian stock exchange.

The Amalgamation Transaction

In connection with the Amalgamation Agreement, the Company will issue, and each holder of RDT Shares will receive, one common share in exchange for each RDT Share held immediately prior to the amalgamation and the Company will issue, and each holder of the 840,000 outstanding RDT Warrants will receive, one warrant (each a "Company Warrant") in exchange for each RDT

13. SUBSEQUENT EVENTS (continued):

The Amalgamation Transaction (continued)

Warrant held immediately prior to the amalgamation, each such Company Warrant having identical terms as the RDT Warrants in respect of exercise price, expiry date and all other material terms and conditions.

On completion of the Transaction, ACME will assume RDT's obligation to pay a corporate finance fee (payable by the issuance of Common Shares) to an arm's length party equal to 7% of the total number of common shares issued and outstanding on completion of the Transaction. The common shares issuable for such fee will be subject to a regulatory hold period expiring four months plus one day after the date on which they are issued.

Closing of the Transaction will be subject to approval by regulatory authorities and compliance with any required governmental and securities regulations. Closing will also be conditional on approval for the listing of the Company's common shares on the CSE. There is no guarantee that the Amalgamation Agreement will close. The Company's shareholders meeting has been called to, among other things: (a) approve the change of the Company's name to "Rapid Dose Therapeutics Corp."; (b) approve entering into and completing the Amalgamation Agreement; and (c) to approve any and all other aspects necessary or advisable for completion of the Transaction and/or other Company business.

The Resulting Issuer

Upon closing of the Transaction, the Company will have approximately 66,310,907 common shares issued and outstanding of which approximately 8% will be held by the existing Company's shareholders, and approximately 85% will be held by the former RDT shareholders. The Company will also have 840,000 Company Warrants outstanding.

On completion of the Transaction, the name of the Company will be changed to "Rapid Dose Therapeutics Corp." or another name acceptable to RDT and the Company.

On completion of the Transaction, 51,806,140 common shares issued by the Company in exchange for RDT Shares (excluding 4,560,000 RDT Shares issued on a recent private placement by RDT at $0.50 per share for gross proceeds of $2,280,000) will be placed in escrow for release commencing on the day on which the common shares first start trading on the CSE (the "Escrow Commencement Date") as follows:

a) 5% (2,590,307 common shares) on the Escrow Commencement Date;
b) 5% (2,590,307 common shares) 6 months after the Escrow Commencement Date;
c) 5% (2,590,307 common shares) 12 months after the Escrow Commencement Date;
d) 5% (2,590,307 common shares) 18 months after the Escrow Commencement Date;
e) 15% (7,770,921 common shares) 24 months after the Escrow Commencement Date;
f) 15% (7,770,921 common shares) 30 months after the Escrow Commencement Date; and
g) 50% (25,903,070 common shares) 36 months after the Escrow Commencement Date.